PR NEWSWIRE

Previous Stories

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

Nov 14 2023 - PR NewsWire

MELBOURNE, Australia, Nov. 14, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a…


6clicks GRC Platform Adds Automated Cybersecurity Incident Tracking and Reporting to Meet New SEC Disclosure Requirements

Nov 14 2023 - PR NewsWire

Platform Now Helps Organizations Compile Details of Qualifying Events Centrally for Tracking, Reporting, and Complete Auditability to Ensure Full Compliance and Ease of…


SOR Reaches New Heights in Moisture-Based Energy

Nov 14 2023 - PR NewsWire

PERTH, Australia, Nov. 14, 2023 /PRNewswire/ — Strategic Elements Ltd (ASX Code: SOR) (Company) is pleased to report that the Energy…


NEXTGEN Group Revolutionizes Technology Services Across Asia with Unique Collaborative Model

Nov 14 2023 - PR NewsWire

SYDNEY, Nov. 14, 2023 /PRNewswire/ — NEXTGEN Group (NEXTGEN), a leading Australian technology services company, is transforming the Asia IT…


TEAM IM Selects Oracle Alloy to Build New Zealand’s First Locally Owned and Operated Hyperscale Cloud

Nov 14 2023 - PR NewsWire

The TEAM Cloud platform will offer more than 100 Oracle Cloud Infrastructure services and meet relevant regulatory and data sovereignty…


PYC’S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

Nov 14 2023 - PR NewsWire

PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug…


Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

Nov 13 2023 - PR NewsWire

MELBOURNE, Australia and PARIS, Nov. 13, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Paris-based Mauna Kea…


Power Up and Pay Less with Massive Savings in EcoFlow’s Black Friday Sale

Nov 13 2023 - PR NewsWire

Save on the incredible DELTA Pro portable power station, as well as huge discounts on a wide range of other…


First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

Nov 13 2023 - PR NewsWire

MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first…


Gillette & Braun sign Major Partnership with Movember

Nov 13 2023 - PR NewsWire

SYDNEY, Nov. 13, 2023 /PRNewswire/ – In Australia, one in five men will be diagnosed with prostate cancer in their lifetime….


Analyse The Market From A Different Angle